Preliminary Clinical Study of NMN Intervention in Mild Ulcerative Colitis

NARecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

March 1, 2025

Study Completion Date

July 30, 2025

Conditions
Ulcerative Colitis Chronic Mild
Interventions
DIETARY_SUPPLEMENT

nicotinamide mononucleotide

Nicotinamide mononucleotide (NMN), a bioactive substance found in a variety of foods, is a precursor for the synthesis of nicotinamide adenine dinucleotide (NAD+). NAD+ plays a crucial role in a variety of biological processes including cell death, senescence, gene expression, neuroinflammation, and DNA repair.

OTHER

placebo

The placebo mimicked the appearance and properties of nicotinamide mononucleotide(NMN) enteric-coated capsules. The specifications, usage and dosage of placebo were the same as those of NMN.

Trial Locations (1)

410013

RECRUITING

The Third Xiangya Hospital of Central South University, Changsha

All Listed Sponsors
lead

The Third Xiangya Hospital of Central South University

OTHER